Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA PETER ALPERS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neuromuscular Medicine

NPI
1801926100
CMS profile
354068
Location
CHATTANOOGA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$85,839.35

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA PETER ALPERS

NPI 1801926100 · CMS profile ID 354068

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neuromuscular Medicine

CHATTANOOGA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801926100?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA PETER ALPERS, NPI 1801926100, CMS profile ID 354068. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801926100?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOSHUA PETER ALPERS, NPI 1801926100, CMS profile ID 354068. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801926100?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOSHUA PETER ALPERS, NPI 1801926100, CMS profile ID 354068, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1801926100?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $85,839.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–170 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Avion Pharmaceuticals $21.5204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926520221 CMS
Biogen, Inc. $21.9503/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923434925 CMS
UCB, Inc. $25.1803/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908042275 CMS
Biogen, Inc. $21.9203/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923464427 CMS
Acorda Therapeutics, Inc $16.9703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920334999 CMS
Kyowa Kirin, Inc. $24.4603/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905050263 CMS
SK Life Science, Inc. $15.1803/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940721703 CMS
Supernus Pharmaceuticals, Inc. $18.9003/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952905061 CMS
Alexion Pharmaceuticals, Inc. $1,680.0003/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915527613 CMS
Biohaven Pharmaceutical Holding Company Ltd. $15.1803/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923524599 CMS
Teva Pharmaceuticals USA, Inc. $19.6703/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954696655 CMS
Alexion Pharmaceuticals, Inc. $20.6902/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914635379 CMS
Alexion Pharmaceuticals, Inc. $420.0002/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914681161 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.6902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923524597 CMS
Sunovion Pharmaceuticals Inc. $14.0702/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921064339 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $12.8501/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940565765 CMS
Genentech USA, Inc. $2,100.0001/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950682501 CMS
Acorda Therapeutics, Inc $16.6601/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920334997 CMS
ACADIA Pharmaceuticals Inc $15.5701/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952371463 CMS
Teva Pharmaceuticals USA, Inc. $18.5701/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954696395 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,367.75 35
PY2020 $16,259.44 23
PY2021 $11,858.79 37
PY2022 $85,839.35 170
PY2023 $142,661.65 194
PY2024 $148,993.23 243
PY2025 $205,097.88 287

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $138,656.76 14
PY2024 Principal investigator $8,200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $4,739.40 11/05/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237149986
Principal investigator 1 ARGENX US, INC. $18,852.21 10/17/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149940
Principal investigator 1 ARGENX US, INC. $16,091.01 08/22/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149934
Principal investigator 1 ARGENX US, INC. $9,341.10 08/01/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237149982
Principal investigator 1 ARGENX US, INC. $12,500.00 06/25/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237149927
Principal investigator 1 Alexion Pharmaceuticals, Inc. $3,608.00 05/22/2025 Non-covered Recipient Entity
ERLANGER INSTITUTE FOR CLINICAL RESEARCH
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185550501
Principal investigator 1 ARGENX US, INC. $27,054.43 05/09/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149931
Principal investigator 1 ARGENX US, INC. $3,500.00 05/02/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237149977
Principal investigator 1 ARGENX US, INC. $12,500.00 03/05/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237149949
Principal investigator 1 ARGENX US, INC. $13,250.00 01/17/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149952
Principal investigator 1 ARGENX US, INC. $1,500.00 01/17/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149957
Principal investigator 1 ARGENX US, INC. $7,760.61 01/17/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149965
Principal investigator 1 ARGENX US, INC. $5,460.00 01/17/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149968
Principal investigator 1 ARGENX US, INC. $2,500.00 01/17/2025 Non-covered Recipient Entity
ERLANGER HEALTH INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237149972